Correvio Pharma (NASDAQ:CORV) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.
Shares of NASDAQ:CORV opened at $5.04 on Thursday. Correvio Pharma has a 12 month low of $1.29 and a 12 month high of $5.24. The company has a market cap of $156.92 million, a P/E ratio of -5.60 and a beta of 0.05. The company has a current ratio of 4.11, a quick ratio of 3.49 and a debt-to-equity ratio of 2.71.
Correvio Pharma (NASDAQ:CORV) last announced its earnings results on Tuesday, August 14th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.23). Correvio Pharma had a negative return on equity of 230.15% and a negative net margin of 69.75%. The firm had revenue of $6.18 million for the quarter, compared to the consensus estimate of $7.16 million. analysts anticipate that Correvio Pharma will post -1.01 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Correvio Pharma stock. Putnam Investments LLC bought a new position in shares of Correvio Pharma Corp (NASDAQ:CORV) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,092,133 shares of the company’s stock, valued at approximately $11,688,000. 45.50% of the stock is currently owned by institutional investors.
Correvio Pharma Company Profile
Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.
See Also: Should You Consider an Index Fund?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.